Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for TRIHEPTANOIN
- Study of Triheptanoin for the Prevention of Hypoglycemia in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)
- A Study to Determine the Effect of Triheptanoin Compared With Even-chain, MCT on MCEs in Pediatric Patients With LC-FAOD
- Anaplerotic Therapy Using Triheptanoin for Patients With Glycogen Storage Disease Type I
- A Pilot Trial of Triheptanoin for People With Amyotrophic Lateral Sclerosis (PALS)
- Compatibility of C7 With Ketogenic Diet in Patients Diagnosed With G1D
- Diet Treatment Glucose Transporter Type 1 Deficiency (G1D)
- Treatment Development of Triheptanoin (G1D)
- Treatment With UX007 for a Single Patient With GLUT1 Deficiency Syndrome
- Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
- Triheptanoin in Mc Ardle
- A Pilot Trial of Triheptanoin for the Preventive Treatment of Migraine
- Treatment of Mitochondrial Dysfunction in Rett Syndrome With Triheptanoin
- Brain Energy and Aging With Triheptanoin
- Study to Assess the Long Term Safety and Efficacy of UX007 in Participants With Glucose Type 1 Deficiency Syndrome (Glut1 DS)
- Triheptanoin (UX007) to Treat Citrate Transporter Deficiency
- A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease
- The Effect of Triheptanoin in Adults With McArdle Disease (Glycogen Storage Disease Type V)
- Pilot Study, Comparative, Single-center, Randomized, Crossover, Double-blind, Against Placebo, Testing the Effectiveness of Triheptanoin Oil in Alternating Hemiplegia of Childhood
- Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Extension Study for Subjects Previously Enrolled in Triheptanoin Studies.
- Triheptanoin Treatment Trial for Patients With Long-chain Fatty Acid Beta-oxidation Defects
- An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency Syndrome
- Triheptanoin (C7 Oil), a Food Supplement, for Glucose Transporter Type I Deficiency (G1D)
- Treatment Development for Glucose Transporter Type I Deficiency Syndrome (G1D)
- Post Study Continuation of C7 for G1D
- Phase II Open Label Study Using Triheptanoin in Patients With Glucose Type 1 Transporter Deficiency GLUT1-DS
- Pilot Study of Triheptanoin in Patients With Glucose Transporter 1 Deficiency Syndrome
- Phase 2 Study of Triheptanoin (UX007) for the Treatment of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
- A Study of UX007 (Triheptanoin) in Participants With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)
- Study of the Acute Effects of Triheptanoin in Heart Failure
- Compassionate Use of Triheptanoin (C7) for Inherited Disorders of Energy Metabolism
- Study of Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorder
- Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects
- Triheptanoin Treatment Trial for Patients With Adult Polyglucosan Body Disease
- Nutritional Therapy of the Deficits of Oxidation Mitochondrial of the Fatty Acids
Clinical trials list
click for details